pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
737
stories
17d
Significant stock movers of October: Biohaven climbs, ArriVent dives
biospace
20d
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
biospace
20d
Assessing Merck and Moderna’s mRNA cancer vaccine
stat
20d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
21d
For Lilly, cash-pay is key in the US and, increasingly, abroad
endpoints
21d
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
biospace
21d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
21d
Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
fiercebiotech
22d
Oura, UC San Diego Health collaborate to study GLP-1 outcomes using continuous smart ring data
fiercebiotech
22d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
22d
STAT+: Senate candidate El-Sayed wants to ‘grill’ RFK Jr., calls him the ‘most incompetent HHS secretary ever’
stat
22d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
22d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
22d
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes
endpoints
22d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
22d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
22d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
22d
5 new drug launches that defied industry expectations
biospace
23d
Lilly's ads can continue after Novo challenge, judge rules
endpoints
23d
STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
stat
23d
Court rejects Novo bid to block Lilly obesity drug ads
biopharma dive
23d
Gubra looks beyond metabolism, hopes for first portfolio company this year
endpoints
23d
STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down
stat
24d
Corxel, an obesity drugmaker, to go public via SPAC deal
biopharma dive
24d
Corxel claims oral obesity drug is in the ‘right lane’ as biotech plans SPAC route to Nasdaq
fiercebiotech
24d
The molecule was fine. The moment wasn’t.
biopharma dive
27d
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
stat
27d
Remembering STAT’s Helen Branswell
stat
27d
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
biospace
27d
STAT+: Alnylam says Huntington’s drug shows promise in early study
stat
← prev
page 4 of 25
next →